Physician profile
Brittany L Hackney
NPI 1245879147
$2,740.45
in general payments reported to CMS, 2019-2025
36 companies · $585 in 2025
The $585 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $544 · 2024: $1,611 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $422.17 | 2023-2025 | |
| Eisai INC. | $252.84 | 2024-2025 | |
| Lundbeck LLC | $191.06 | 2023-2024 | Vyepti |
| Argenx US, INC. | $180.28 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $172.39 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $168.15 | 2024-2025 | Hyqvia |
| Novartis Pharmaceuticals Corporation | $158.39 | 2023-2024 | |
| Ucb, INC. | $157.23 | 2024 | Fintepla, Rystiggo |
| Lilly USA, LLC | $99.08 | 2023-2025 | Amyvid, Kisunla, Emgality |
| Jazz Pharmaceuticals INC. | $60.19 | 2024 | |
| Sumitomo Pharma America, INC. | $58.70 | 2024 | Aptiom |
| Neurelis, INC. | $57.41 | 2023 | Valtoco |
| Genentech USA, INC. | $57.04 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Teva Pharmaceuticals USA, INC. | $55.62 | 2023-2025 | Austedo Xr, Ajovy |
| Grifols USA, LLC | $55.20 | 2024 | Gamunex-C |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $54.41 | 2023 | Trudhesa |
| Pfizer INC. | $48.93 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $48.60 | 2024-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $38.30 | 2023-2024 | Nuplazid |
| Xeris Pharmaceuticals, INC. | $38.02 | 2024-2025 | Keveyis |
| Otsuka America Pharmaceutical, INC. | $37.78 | 2023 | Rexulti, Nuedexta |
| Biogen, INC. | $35.60 | 2024 | Tysabri, Vumerity |
| Azurity Pharmaceuticals, INC. | $28.29 | 2023-2024 | Horizant, Horizant |
| Amneal Pharmaceuticals LLC | $28.21 | 2023-2024 | Rytary |
| Mallinckrodt Hospital Products INC. | $23.75 | 2025 | Acthar |
| Catalyst Pharmaceuticals, INC. | $23.42 | 2024 | |
| Livanova USA, INC. | $23.01 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Tg Therapeutics, INC. | $22.18 | 2025 | |
| Emd Serono, INC. | $21.81 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.56 | 2023 | Rexulti |
| Upsher-Smith Laboratories LLC | $18.81 | 2024 | |
| Amgen INC. | $18.17 | 2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $18.03 | 2025 | Ultomiris |
| Vanda Pharmaceuticals INC. | $16.42 | 2025 | Ponvory |
| Csl Behring | $15.68 | 2024 | Hizentra |
| Celgene Corporation | $13.72 | 2025 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Hackney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.